TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
4.620
+0.020 (0.43%)
Sep 16, 2025, 12:40 PM EDT - Market open
TriSalus Life Sciences Stock Forecast
Stock Price Forecast
The 5 analysts that cover TriSalus Life Sciences stock have a consensus rating of "Strong Buy" and an average price target of $10.9, which forecasts a 135.93% increase in the stock price over the next year. The lowest target is $10 and the highest is $12.5.
Price Target: $10.9 (+135.93%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2025.
Analyst Ratings
The average analyst rating for TriSalus Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +138.10% | Mar 28, 2025 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +138.10% | Jan 24, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $10 | Buy | Initiates | $10 | +116.45% | Dec 17, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +138.10% | Nov 15, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +138.10% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
46.14M
from 29.43M
Increased by 56.79%
Revenue Next Year
71.13M
from 46.14M
Increased by 54.15%
EPS This Year
-0.82
from -1.31
EPS Next Year
-0.12
from -0.82
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 50.4M | 88.8M | |||
| Avg | 46.1M | 71.1M | |||
| Low | 43.1M | 60.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.3% | 92.4% | |||
| Avg | 56.8% | 54.1% | |||
| Low | 46.5% | 30.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.56 | 0.51 | |
| Avg | -0.82 | -0.12 | |
| Low | -0.87 | -0.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.